🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsInternationalCanadian GLP-1 coverage — 12 month update Page 4

Canadian GLP-1 coverage — 12 month update

Dr.SleepRoch Tue, Dec 17, 2024 at 4:46 AM 52 replies 2,746 viewsPage 4 of 11
NurseLeah_Nash
Member
278
1,234
Sep 2024
Nashville, TN
Dec 19, 2024 at 6:17 AM#16

Adding the clinical framing, because it changes how the question reads. There is a difference between no evidence and evidence of no effect, and this subject is one where the two get swapped freely in both directions.

39 12RegAffairsDC, BiostatsBrad, PeptideSynthNJ and 36 others
Reply Quote Save Share Report
JessicaM_2024
Member
823
3,456
Mar 2024
Portland, OR
Dec 19, 2024 at 8:46 AM#17
NurseLeah_Nash said:
There is a difference between no evidence and evidence of no effect, and this subject is one where the two get swapped freely in both directions.

Same experience, arrived at from the opposite direction. Nothing to add that would improve it.

Last edited: Dec 19, 2024 at 9:46 AM
40 13NicoleRaleigh, james_edin, FranDenver and 37 others
Reply Quote Save Share Report
cory_ATX
Member
456
2,123
Jul 2024
Austin, TX
Dec 19, 2024 at 11:16 AM#18
NurseLeah_Nash said:
There is a difference between no evidence and evidence of no effect, and this subject is one where the two get swapped freely in both directions.

Adding the part of the answer the thread has not reached. The mechanism and the magnitude are separate questions. Agreeing that something happens says nothing about whether it happens enough to act on.

41 14mona_PHX, andrew_nyc, Dr.EndoEP and 38 others
Reply Quote Save Share Report

Sigma-Aldrich — Research-Grade Standards

Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.

Shop Reference Standards
raj_cambridge
Member
489
2,123
Jun 2024
Cambridge, MA
Dec 19, 2024 at 1:46 PM#19

Adding the numbers, since they settle part of this. Keep the original post as written when you update it, and add the correction underneath. An edited-away mistake is invisible to the next person who makes it.

42 15PharmHunterJen, TomTeleRx, DoseLogDan and 39 others
Reply Quote Save Share Report
mike_mod
Moderator
7,234
19,823
Nov 2023
New York
Online
Dec 19, 2024 at 4:16 PM#20

Moderator note: leaving this open. It is being argued well and the disagreement is the useful part. Tagging this one for the weekly digest.

Last edited: Dec 19, 2024 at 6:16 PM
14 12PurityPaulOR, MaxMetOK, MounjBrad and 11 others
Reply Quote Save Share Report

Similar Threads

EU EMA compounding guidance — 2026 regulatory update9 replies
UK NHS GLP-1 prescribing — NICE TA875 and access guide7 replies
Australian TGA scheduling changes — peptide access 20268 replies
Canadian GLP-1 coverage — provincial formulary comparison6 replies
Purchasing GLP-1 in Mexico — legality, quality, and safety concerns6 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register